Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells

Takeo Fujita, Hiroyoshi Doihara, Kazuhiro Washio, Kensuke Kawasaki, Daisuke Takabatake, Hirotoshi Takahashi, Kazunori Tsukuda, Yutaka Ogasawara, Nobuyoshi Shimizu

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

PTEN (phosphatase and tension homolog deleted on chromosome 10) has been shown to be inactivated in a wide range of cancers and the role of this gene product is associated with the suppression of the phosphatidylinositol-3-kinase (PI3K)/Akt pathway in many cancers. Recently, some reports demonstrated that the degree of PTEN expression could predict trastuzumab chemosensitivity in ErbB2-overexpressing breast cancer. Here, we demonstrate the possible involvement of a proteasome inhibitor (PS341) in PTEN expression and elucidate the influence of PI3K/Akt, one of the main cascades of the ErbB2 downstream pathway, and discuss the role of the proteasome inhibitors in trastuzumab resistance. ErbB2-overexpressing SKBR3 human breast cancer cells and trastuzumab-resistant SKBR3/R cells were analyzed in this study. We show that the expression of phosphorylated Akt was highly increased in trastuzumab-resistant cells, although the expression of PI3K, phosphorylated PI3K and non-phosphorylated Akt was unchanged in comparison with wild-type SKBR3 cells. However, following treatment with PS341, the level of phosphorylated Akt was decreased in a dose-dependent manner. Conversely, the level of PTEN was increased in the same fashion. PS341 showed sufficient cytotoxicity in resistant cells in combination with trastuzumab and the efficacy of trastuzumab was inclined to be better in resistant cells under PS341 treatment. Remarkable activity of Akt was observed in trastuzumab-resistant SKBR3 breast cancer cells and this phenomenon could be associated with the decreased expression of PTEN. The proteasome inhibitor PS341 could increase the level of PTEN and inhibit the downstream pathway of ErbB2, interfering with phosphorylation of Akt.

Original languageEnglish
Pages (from-to)455-462
Number of pages8
JournalAnti-Cancer Drugs
Volume17
Issue number4
DOIs
Publication statusPublished - Apr 2006

Fingerprint

Proteasome Inhibitors
Phosphatidylinositol 3-Kinase
Growth
Breast Neoplasms
PTEN Phosphohydrolase
Chromosomes, Human, Pair 10
Neoplasm Genes
Bortezomib
Trastuzumab
Phosphorylation

Keywords

  • Akt
  • Bortezomib
  • Breast cancer
  • Proteasome inhibitor
  • PTEN
  • Trastuzumab

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells. / Fujita, Takeo; Doihara, Hiroyoshi; Washio, Kazuhiro; Kawasaki, Kensuke; Takabatake, Daisuke; Takahashi, Hirotoshi; Tsukuda, Kazunori; Ogasawara, Yutaka; Shimizu, Nobuyoshi.

In: Anti-Cancer Drugs, Vol. 17, No. 4, 04.2006, p. 455-462.

Research output: Contribution to journalArticle

Fujita, Takeo ; Doihara, Hiroyoshi ; Washio, Kazuhiro ; Kawasaki, Kensuke ; Takabatake, Daisuke ; Takahashi, Hirotoshi ; Tsukuda, Kazunori ; Ogasawara, Yutaka ; Shimizu, Nobuyoshi. / Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells. In: Anti-Cancer Drugs. 2006 ; Vol. 17, No. 4. pp. 455-462.
@article{24190872f0fd4fa0b67972df34aa5857,
title = "Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells",
abstract = "PTEN (phosphatase and tension homolog deleted on chromosome 10) has been shown to be inactivated in a wide range of cancers and the role of this gene product is associated with the suppression of the phosphatidylinositol-3-kinase (PI3K)/Akt pathway in many cancers. Recently, some reports demonstrated that the degree of PTEN expression could predict trastuzumab chemosensitivity in ErbB2-overexpressing breast cancer. Here, we demonstrate the possible involvement of a proteasome inhibitor (PS341) in PTEN expression and elucidate the influence of PI3K/Akt, one of the main cascades of the ErbB2 downstream pathway, and discuss the role of the proteasome inhibitors in trastuzumab resistance. ErbB2-overexpressing SKBR3 human breast cancer cells and trastuzumab-resistant SKBR3/R cells were analyzed in this study. We show that the expression of phosphorylated Akt was highly increased in trastuzumab-resistant cells, although the expression of PI3K, phosphorylated PI3K and non-phosphorylated Akt was unchanged in comparison with wild-type SKBR3 cells. However, following treatment with PS341, the level of phosphorylated Akt was decreased in a dose-dependent manner. Conversely, the level of PTEN was increased in the same fashion. PS341 showed sufficient cytotoxicity in resistant cells in combination with trastuzumab and the efficacy of trastuzumab was inclined to be better in resistant cells under PS341 treatment. Remarkable activity of Akt was observed in trastuzumab-resistant SKBR3 breast cancer cells and this phenomenon could be associated with the decreased expression of PTEN. The proteasome inhibitor PS341 could increase the level of PTEN and inhibit the downstream pathway of ErbB2, interfering with phosphorylation of Akt.",
keywords = "Akt, Bortezomib, Breast cancer, Proteasome inhibitor, PTEN, Trastuzumab",
author = "Takeo Fujita and Hiroyoshi Doihara and Kazuhiro Washio and Kensuke Kawasaki and Daisuke Takabatake and Hirotoshi Takahashi and Kazunori Tsukuda and Yutaka Ogasawara and Nobuyoshi Shimizu",
year = "2006",
month = "4",
doi = "10.1097/01.cad.0000198910.90819.06",
language = "English",
volume = "17",
pages = "455--462",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells

AU - Fujita, Takeo

AU - Doihara, Hiroyoshi

AU - Washio, Kazuhiro

AU - Kawasaki, Kensuke

AU - Takabatake, Daisuke

AU - Takahashi, Hirotoshi

AU - Tsukuda, Kazunori

AU - Ogasawara, Yutaka

AU - Shimizu, Nobuyoshi

PY - 2006/4

Y1 - 2006/4

N2 - PTEN (phosphatase and tension homolog deleted on chromosome 10) has been shown to be inactivated in a wide range of cancers and the role of this gene product is associated with the suppression of the phosphatidylinositol-3-kinase (PI3K)/Akt pathway in many cancers. Recently, some reports demonstrated that the degree of PTEN expression could predict trastuzumab chemosensitivity in ErbB2-overexpressing breast cancer. Here, we demonstrate the possible involvement of a proteasome inhibitor (PS341) in PTEN expression and elucidate the influence of PI3K/Akt, one of the main cascades of the ErbB2 downstream pathway, and discuss the role of the proteasome inhibitors in trastuzumab resistance. ErbB2-overexpressing SKBR3 human breast cancer cells and trastuzumab-resistant SKBR3/R cells were analyzed in this study. We show that the expression of phosphorylated Akt was highly increased in trastuzumab-resistant cells, although the expression of PI3K, phosphorylated PI3K and non-phosphorylated Akt was unchanged in comparison with wild-type SKBR3 cells. However, following treatment with PS341, the level of phosphorylated Akt was decreased in a dose-dependent manner. Conversely, the level of PTEN was increased in the same fashion. PS341 showed sufficient cytotoxicity in resistant cells in combination with trastuzumab and the efficacy of trastuzumab was inclined to be better in resistant cells under PS341 treatment. Remarkable activity of Akt was observed in trastuzumab-resistant SKBR3 breast cancer cells and this phenomenon could be associated with the decreased expression of PTEN. The proteasome inhibitor PS341 could increase the level of PTEN and inhibit the downstream pathway of ErbB2, interfering with phosphorylation of Akt.

AB - PTEN (phosphatase and tension homolog deleted on chromosome 10) has been shown to be inactivated in a wide range of cancers and the role of this gene product is associated with the suppression of the phosphatidylinositol-3-kinase (PI3K)/Akt pathway in many cancers. Recently, some reports demonstrated that the degree of PTEN expression could predict trastuzumab chemosensitivity in ErbB2-overexpressing breast cancer. Here, we demonstrate the possible involvement of a proteasome inhibitor (PS341) in PTEN expression and elucidate the influence of PI3K/Akt, one of the main cascades of the ErbB2 downstream pathway, and discuss the role of the proteasome inhibitors in trastuzumab resistance. ErbB2-overexpressing SKBR3 human breast cancer cells and trastuzumab-resistant SKBR3/R cells were analyzed in this study. We show that the expression of phosphorylated Akt was highly increased in trastuzumab-resistant cells, although the expression of PI3K, phosphorylated PI3K and non-phosphorylated Akt was unchanged in comparison with wild-type SKBR3 cells. However, following treatment with PS341, the level of phosphorylated Akt was decreased in a dose-dependent manner. Conversely, the level of PTEN was increased in the same fashion. PS341 showed sufficient cytotoxicity in resistant cells in combination with trastuzumab and the efficacy of trastuzumab was inclined to be better in resistant cells under PS341 treatment. Remarkable activity of Akt was observed in trastuzumab-resistant SKBR3 breast cancer cells and this phenomenon could be associated with the decreased expression of PTEN. The proteasome inhibitor PS341 could increase the level of PTEN and inhibit the downstream pathway of ErbB2, interfering with phosphorylation of Akt.

KW - Akt

KW - Bortezomib

KW - Breast cancer

KW - Proteasome inhibitor

KW - PTEN

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=33748159249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748159249&partnerID=8YFLogxK

U2 - 10.1097/01.cad.0000198910.90819.06

DO - 10.1097/01.cad.0000198910.90819.06

M3 - Article

C2 - 16550004

AN - SCOPUS:33748159249

VL - 17

SP - 455

EP - 462

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 4

ER -